Evidence map›Paper›PMID 39581190›Full record

ArticleGenes to cells : devoted to molecular & cellular mechanisms2025

Generation of Monosomy 21q Human iPS Cells by CRISPR/Cas9-Mediated Interstitial Megabase Deletion.

Masaya Egawa, Narumi Uno, Rina Komazaki, Yusuke Ohkame, Kyotaro Yamazaki, Chihiro Yoshimatsu, Yuki Ishizu, Yusaku Okano, Hitomaru Miyamoto, Mitsuhiko Osaki and 5 more

Abstract read
In one paragraph

Article in Genes to cells : devoted to molecular & cellular mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Masaya EgawaLaboratory of Bioengineering, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Narumi UnoLaboratory of Bioengineering, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Rina KomazakiLaboratory of Bioengineering, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Yusuke OhkameChromosome Engineering Research Center, Tottori University, Tottori, Japan.
Kyotaro YamazakiChromosome Engineering Research Group, the Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, Okazaki, Japan.
Chihiro YoshimatsuDepartment of Chromosome Biomedical Engineering, Integrated Medical Sciences, Graduate School of Medical Sciences, Tottori University, Tottori, Japan.
Yuki IshizuLaboratory of Bioengineering, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Yusaku OkanoLaboratory of Bioengineering, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Hitomaru MiyamotoDepartment of Chromosome Biomedical Engineering, Integrated Medical Sciences, Graduate School of Medical Sciences, Tottori University, Tottori, Japan.
Mitsuhiko OsakiChromosome Engineering Research Center, Tottori University, Tottori, Japan.
Teruhiko SuzukiStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Kazuyoshi HosomichiLaboratory of Computational Genomics, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Yasunori AizawaSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.ORCID https://orcid.org/0000-0002-4524-4194
Yasuhiro KazukiChromosome Engineering Research Center, Tottori University, Tottori, Japan.
Kazuma TomizukaLaboratory of Bioengineering, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.ORCID https://orcid.org/0009-0001-7523-064X

Funding

CREST, Japan Science and Technology Agency JPMJCR18S4Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences 21-101Japan Agency for Medical Research and Development JP24ama121046Japan Agency for Medical Research and Development JP24bm1123038Japan Agency for Medical Research and Development JP24gm0010010SPRING, Japan Science and Technology Agency JPMJSP2134
6 · The paper itself

Abstract

Missing an entire chromosome or chromosome arm in normal diploid cells has a deleterious impact on cell viability, which may contribute to the development of specific birth defects. Nevertheless, the effects of chromosome loss in human cells have remained unexplored due to the lack of suitable model systems. Here, we developed an efficient, selection-free approach to generate partial monosomy in human induced pluripotent stem cells (iPSCs). The introduction of Cas9 proteins and a pair of gRNAs induces over megabase-sized interstitial chromosomal deletions. Using human chromosome 21 (HSA21) as a model, partial monosomy 21q (PM21q) iPSC lines with deletions ranging from 4.5 to 27.9 Mb were isolated. A 33.6 Mb deletion, encompassing all protein-coding genes on 21q, was also achieved, establishing the first 21q monosomy human iPSC line. Transcriptome and proteome analyses revealed that the abundances of mRNA and protein encoded by the majority of genes in the monosomic regions are half of the diploid expression level, indicating an absence of dosage compensation. The ability to generate customized partial monosomy cell lines on an isogenic, karyotypically normal background should facilitate the gain of novel insights into the impact of chromosome loss on cellular fitness.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 21CRISPR-Cas SystemsInduced Pluripotent Stem CellsCell LineHumansMonosomychromosome lossCRISPR/Cas9dosage compensationhaploinsufficiencyiPS cellmonosomy

Identifiers

PMID39581190
PMCPMC11655957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.